Spruce Biosciences, Inc.
SPRBSpruce Biosciences, Inc. in brief
Spruce Biosciences, Inc. is a listed company in the Biotechnology industry, based in South San Francisco, California, USA. Its market value was $130 M on 26 October 2026, which makes it the 17,795th largest listed company in the world and the 3,383rd largest in the USA on this site. Javier B. Szwarcberg is its chief executive. Its shares trade under the symbol SPRB (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Spruce Biosciences, Inc.
Spruce Biosciences, Inc. is a Late Stage Biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. It is having 15 employees as on 2020. The headquarters is in USA.
Spruce Biosciences, Inc. timeline
- 2020
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 9 October 2020; shares registered for exchange trading on 5 October 2020.
Events of Spruce Biosciences, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,652 (Jan 2021) · #4,493 (Jan 2022) · #5,174 (Dec 2022) · #4,323 (Jul 2023) · #3,594 (Jan 2024) · #2,097 (Mar 2026) · #3,239 (Aug 2026) · #3,349 (Oct 2026) · #3,387 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 3.1×
- Free cash flow yield
- -43.1%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -91.7%
- Liabilities / assets
- 19.8%
- Net debt
- $-49M
- Revenue growth
- -51.3%
- R&D / revenue
- 945.4%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-37M | $-39M | — |
| Dec 2024 | $5M | -51.3% | $-56M | $-53M | -1080.2% |
| Dec 2023 | $10M | — | $-52M | $-48M | -474.9% |
| Dec 2022 | — | — | $-47M | $-46M | — |
| Dec 2021 | — | — | $-42M | $-42M | — |
| Dec 2020 | — | — | $-29M | $-30M | — |
| Dec 2019 | — | — | $-13M | $-13M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-33M | — | — | $-50.83 | — |
| Dec 2024 | $-56M | $0M | $-56M | $-96.40 | — |
| Dec 2023 | $-33M | $0M | $-33M | $-1.24 | — |
| Dec 2022 | $-42M | $0M | $-42M | $-1.96 | — |
| Dec 2021 | $-36M | $0M | $-36M | $-1.81 | — |
| Dec 2020 | $-28M | $0M | $-28M | $-4.93 | — |
| Dec 2019 | $-13M | $0M | $-13M | $-17.12 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-24M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 9, 202610-QQuarterly report · period to Sep 2026
- Nov 9, 20268-KCurrent reportResults of operations
- Aug 12, 202610-QQuarterly report · period to Jun 2026
- Aug 12, 20268-KCurrent reportResults of operations
- Jul 27, 20268-KCurrent reportDirectors or officers changed
- May 26, 20268-KCurrent reportShareholder vote
- May 13, 202610-QQuarterly report · period to Mar 2026
- May 13, 20268-KCurrent reportResults of operations
- Apr 22, 20268-KCurrent reportMaterial agreement · Other events
- Apr 9, 2026DEF 14AProxy statement
- Mar 20, 20268-KCurrent reportAgreement ended
- Mar 9, 20268-KCurrent reportMaterial agreement · Agreement ended · Results of operations · Directors or officers changed
Official filings of Spruce Biosciences, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-37 M
- Net income
- $-39 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $53 M
- Total liabilities
- $11 M
- Total equity
- $43 M
As of December-2025
Top 70 institutional investors in Spruce Biosciences, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | AIGH Capital Management LLC | 250,000 | 0 (0.00%) | 8.70% | $12 M | Nov 2, 2026 |
| 2 | Orbimed Advisors LLC | 242,800 | +42,800 (+21.40%) | 8.45% | $12 M | Nov 16, 2026 |
| 3 | BlackRock, Inc. | 192,015 | +4,179 (+2.22%) | 6.68% | $9 M | Nov 13, 2026 |
| 4 | Millennium Management LLC | 136,675 | -24,306 (-15.10%) | 4.76% | $7 M | Nov 16, 2026 |
| 5 | Vanguard Capital Management LLC | 119,331 | 0 (0.00%) | 4.15% | $6 M | Nov 13, 2026 |
| 6 | Ikarian Capital, LLC | 101,356 | -20,000 (-16.48%) | 3.53% | $5 M | Nov 16, 2026 |
| 7 | Citadel Advisors LLC | 90,610 | +38,705 (+74.57%) | 3.15% | $4 M | Nov 16, 2026 |
| 8 | Geode Capital Management, LLC | 66,757 | -3,791 (-5.37%) | 2.32% | $3 M | Nov 6, 2026 |
| 9 | Cable Car Capital, LP | 60,000 | 0 (0.00%) | 2.09% | $3 M | Nov 16, 2026 |
| 10 | State Street Corp | 59,032 | +8,582 (+17.01%) | 2.05% | $3 M | Nov 12, 2026 |
| 11 | Alyeska Investment Group, L.P. | 51,671 | -30,000 (-36.73%) | 1.80% | $3 M | Nov 16, 2026 |
| 12 | ADAR1 Capital Management, LLC | 51,646 | -16,071 (-23.73%) | 1.80% | $3 M | Nov 16, 2026 |
| 13 | Point72 Asset Management, L.P. | 44,258 | +15,980 (+56.51%) | 1.54% | $2 M | Nov 16, 2026 |
| 14 | Diadema Partners LP | 40,435 | +10,435 (+34.78%) | 1.41% | $2 M | Nov 16, 2026 |
| 15 | Eversept Partners, LP | 39,840 | -160 (-0.40%) | 1.39% | $2 M | Nov 16, 2026 |
| 16 | Carlyle Group Inc. | 38,620 | 0 (0.00%) | 1.34% | $2 M | Nov 6, 2026 |
| 17 | Boothbay Fund Management, LLC | 35,145 | -6,935 (-16.48%) | 1.22% | $2 M | Nov 16, 2026 |
| 18 | Quinn Opportunity Partners LLC | 26,810 | 0 (0.00%) | 0.93% | $1 M | Nov 10, 2026 |
| 19 | Rosalind Advisors, Inc. | 26,517 | +6,517 (+32.58%) | 0.92% | $1 M | Nov 16, 2026 |
| 20 | Knott David M Jr | 26,085 | +6,085 (+30.43%) | 0.91% | $1 M | Nov 12, 2026 |
| 21 | ExodusPoint Capital Management, LP | 22,000 | 0 (0.00%) | 0.77% | $1 M | Nov 16, 2026 |
| 22 | Northern Trust Corp | 19,988 | -1,095 (-5.19%) | 0.70% | $1 M | Nov 16, 2026 |
| 23 | XTX Topco Ltd | 19,690 | New | 0.69% | $1 M | Nov 16, 2026 |
| 24 | Vanguard Fiduciary Trust Co | 19,077 | +716 (+3.90%) | 0.66% | $1 M | Nov 13, 2026 |
| 25 | Ameriprise Financial Inc | 18,870 | +36 (+0.19%) | 0.66% | $1 M | Nov 16, 2026 |
Show all 70: investors 26 to 70
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Vanguard Portfolio Management LLC | 17,180 | -1,316 (-7.12%) | 0.60% | $1 M | Nov 13, 2026 |
| 27 | Balyasny Asset Management L.P. | 12,138 | 0 (0.00%) | 0.42% | $1 M | Nov 16, 2026 |
| 28 | Persistent Asset Partners Ltd | 10,334 | +2,657 (+34.61%) | 0.36% | $1 M | Nov 13, 2026 |
| 29 | Engineers Gate Manager LP | 9,636 | New | 0.34% | $0 M | Nov 16, 2026 |
| 30 | Morgan Stanley | 9,209 | +4,798 (+108.77%) | 0.32% | $0 M | Nov 13, 2026 |
| 31 | Dimensional Fund Advisors LP | 8,788 | -25 (-0.28%) | 0.31% | $0 M | Nov 4, 2026 |
| 32 | UBS Group AG | 7,910 | -15,471 (-66.17%) | 0.28% | $0 M | Nov 10, 2026 |
| 33 | Jane Street Group, LLC | 7,549 | New | 0.26% | $0 M | Nov 12, 2026 |
| 34 | State Board Of Administration Of Florida Retirement System | 7,182 | 0 (0.00%) | 0.25% | $0 M | Nov 13, 2026 |
| 35 | Bank of New York Mellon Corp | 6,819 | +40 (+0.59%) | 0.24% | $0 M | Nov 5, 2026 |
| 36 | Goldman Sachs Group Inc | 6,766 | -25,582 (-79.08%) | 0.24% | $0 M | Nov 16, 2026 |
| 37 | Charles Schwab Investment Management Inc | 6,072 | +176 (+2.99%) | 0.21% | $0 M | Nov 16, 2026 |
| 38 | FMR LLC | 3,589 | +3,246 (+946.36%) | 0.12% | $0 M | Nov 10, 2026 |
| 39 | Rhumbline Advisers | 3,453 | -66 (-1.88%) | 0.12% | $0 M | Nov 10, 2026 |
| 40 | Nuveen, LLC | 2,501 | New | 0.09% | $0 M | Nov 10, 2026 |
| 41 | Deutsche Bank AG\ | 2,323 | -329 (-12.41%) | 0.08% | $0 M | Nov 6, 2026 |
| 42 | New York State Common Retirement Fund | 1,900 | 0 (0.00%) | 0.07% | $0 M | Nov 17, 2026 |
| 43 | Tower Research Capital LLC (TRC) | 1,440 | +1,194 (+485.37%) | 0.05% | $0 M | Nov 16, 2026 |
| 44 | Jpmorgan Chase & Co | 1,411 | +284 (+25.20%) | 0.05% | $0 M | Nov 12, 2026 |
| 45 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 1,192 | -60 (-4.79%) | 0.04% | $0 M | Nov 16, 2026 |
| 46 | Barclays PLC | 1,150 | +476 (+70.62%) | 0.04% | $0 M | Nov 6, 2026 |
| 47 | Vanguard Global Advisers, LLC | 1,133 | +681 (+150.66%) | 0.04% | $0 M | Nov 13, 2026 |
| 48 | Lion Point Capital, LP | 1,000 | 0 (0.00%) | 0.03% | $0 M | Nov 16, 2026 |
| 49 | Police & Firemen's Retirement System of New Jersey | 864 | 0 (0.00%) | 0.03% | $0 M | Nov 9, 2026 |
| 50 | BNP Paribas Financial Markets | 617 | +164 (+36.20%) | 0.02% | $0 M | Nov 12, 2026 |
| 51 | Wells Fargo & Company/mn | 553 | -1,776 (-76.26%) | 0.02% | $0 M | Nov 16, 2026 |
| 52 | PNC Financial Services Group, Inc. | 355 | New | 0.01% | $0 M | Nov 6, 2026 |
| 53 | Royal Bank Of Canada | 315 | +149 (+89.76%) | 0.01% | $0 M | Nov 16, 2026 |
| 54 | Russell Investments Group, Ltd. | 275 | +58 (+26.73%) | 0.01% | $0 M | Nov 6, 2026 |
| 55 | Legal & General Group Plc | 264 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 56 | Ameritas Investment Partners, Inc. | 247 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 57 | SBI Securities Co., Ltd. | 201 | 0 (0.00%) | 0.01% | $0 M | Oct 22, 2026 |
| 58 | Pinnacle Wealth Planning Services, Inc. | 167 | New | 0.01% | $0 M | Oct 27, 2026 |
| 59 | Citigroup Inc | 122 | -1,143 (-90.36%) | 0.00% | $0 M | Nov 4, 2026 |
| 60 | Parkside Financial Bank & Trust | 97 | New | 0.00% | $0 M | Oct 27, 2026 |
| 61 | GAMMA Investing LLC | 85 | New | 0.00% | $0 M | Oct 8, 2026 |
| 62 | Sterling Capital Management LLC | 59 | +16 (+37.21%) | 0.00% | $0 M | Oct 22, 2026 |
| 63 | Jones Financial Companies Lllp | 30 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 64 | SJS Investment Consulting Inc. | 17 | New | 0.00% | $0 M | Oct 26, 2026 |
| 65 | Caldwell Sutter Capital, Inc. | 13 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
| 66 | Root Financial Partners, LLC | 8 | New | 0.00% | $0 M | Oct 21, 2026 |
| 67 | Cassaday & Co Wealth Management LLC | 2 | 0 (0.00%) | 0.00% | $0 M | Oct 27, 2026 |
| 68 | Allworth Financial LP | 1 | New | 0.00% | $0 M | Nov 17, 2026 |
| 69 | Farther Finance Advisors, LLC | 1 | New | 0.00% | $0 M | Oct 8, 2026 |
| 70 | Aster Capital Management (DIFC) Ltd | 1 | New | 0.00% | $0 M | Nov 12, 2026 |
Mutual funds holding Spruce Biosciences, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 84,935 | $5 M | 3.0% | <0.01% | +1306% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 65,222 | $4 M | 2.3% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 31,892 | $2 M | 1.1% | <0.01% | +168% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 29,694 | $1 M | 1.0% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 16,862 | $1 M | 0.59% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 8,665 | $0 M | 0.30% | 0.03% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 6,207 | $0 M | 0.22% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 6,797 | $0 M | 0.24% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 5,566 | $0 M | 0.19% | <0.01% | −2.0% | May 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 4,827 | $0 M | 0.17% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 3,751 | $0 M | 0.13% | <0.01% | +192% | Jul 31, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 3,660 | $0 M | 0.13% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 2,837 | $0 M | 0.10% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 2,787 | $0 M | 0.10% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 2,100 | $0 M | 0.07% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 1,920 | $0 M | 0.07% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 1,652 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 1,968 | $0 M | 0.07% | <0.01% | +401% | Jul 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 1,419 | $0 M | 0.05% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 1,345 | $0 M | 0.05% | <0.01% | +1021% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P. | 1,551 | $0 M | 0.05% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 1,200 | $0 M | 0.04% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 1,159 | $0 M | 0.04% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 1,299 | $0 M | 0.05% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Tiff Multi-Asset FundTIFF Advisory Services, LLC | 832 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 817 | $0 M | 0.03% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 768 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 660 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 623 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 610 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 610 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 768 | $0 M | 0.03% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 604 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 582 | $0 M | 0.02% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 574 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 681 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 NVIT GS Small Cap Equity Insights FundNATIONWIDE FUND ADVISORS | 493 | $0 M | 0.02% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Variable Insurance Trust Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P. | 479 | $0 M | 0.02% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 425 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 410 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 347 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 294 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP | 371 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 318 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 247 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 303 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 217 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 264 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 239 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 170 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 132 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 113 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 105 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 84 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 69 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 62 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 53 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 32 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 58 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Spruce Biosciences, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Javier B. SzwarcbergCHIEF EXECUTIVE OFFICER, Director | Grant or award | +266 | $4.530 | $1 K | 19,270 | Form 4 |
| filed | Javier B. SzwarcbergCHIEF EXECUTIVE OFFICER, Director | Grant or award | +4,690 | $4.530 | $21 K | 19,004 | Form 4 |
| filed | Javier B. SzwarcbergCHIEF EXECUTIVE OFFICER, Director | Option exercise | +1,480 | — | — | 14,478 | Form 4 |
| filed | Samir M. GharibPRESIDENT AND CFO | Option exercise | +496 | — | — | 8,112 | Form 4 |
| filed | Javier B. SzwarcbergCHIEF EXECUTIVE OFFICER, Director | Shares withheld for tax | -752 | $80.67 | $61 K | 13,726 | Form 4 |
| filed | Samir M. GharibPRESIDENT AND CFO | Shares withheld for tax | -178 | $80.67 | $14 K | 7,934 | Form 4 |
| filed | Samir M. GharibPRESIDENT AND CFO | Option exercise | +513 | — | — | 8,447 | Form 4 |
| filed | Javier B. SzwarcbergCHIEF EXECUTIVE OFFICER, Director | Option exercise | +1,196 | — | — | 14,922 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Spruce Biosciences, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-6.54 reverse split
Trading halts
- 2025-10-07 14:56 UTC, code LUDP, resumed 15:01 UTC
- 2025-10-07 13:48 UTC, code LUDP, resumed 13:53 UTC
- 2025-10-07 13:32 UTC, code LUDP, resumed 13:37 UTC
- 2025-10-06 19:48 UTC, code LUDP, resumed 20:00 UTC
- 2025-10-06 19:27 UTC, code LUDP, resumed 19:47 UTC
Fails to deliver
- : 190 shares at $45.15
- : 106 shares at $40.40
- : 990 shares at $38.98
- : 713 shares at $45.42
- : 95 shares at $47.27
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Spruce Biosciences, Inc. scorecard#
Passes 3 of the 15 checks that could be worked out: strongest in financial health (3 of 5), weakest in valuation (0 of 4). Fiscal year 2025; market cap of Oct 26, 2026.
Valuation0 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median3.0×Price to book 3.0× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-43.1%Free cash flow is -43.1% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-50.83 vs -96.40Diluted EPS -50.83 in fiscal 2025 against -96.40 the year before (report's currency).
- ✗Net income higher than five years earlier-$39 M-$39 M in fiscal 2025 against -$30 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$39 MNet income -$39 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-109.2%-109.2% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health3 of 5
- ✓Short-term assets cover short-term liabilities5.2×Current ratio 5.16 at the end of fiscal 2025.
- ✓Debt below equity0.0×Debt to equity 0.00 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $49 M at the end of fiscal 2025.
- ✗Operating income covers interest five times-405.7×Operating income -405.7 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year39.5%Diluted shares up 39.5% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Spruce Biosciences, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 0−100%— | 4.9−51.3%100% | 10—100% | 0—— | — | — | — | |
| Research and development | 20−57.9%— | 46−6.1%945% | 49+40.4%490% | 35+14.7%— | 31+28.7%— | 24+121%— | 11—— | |
| General and administrative | 17+16.0%— | 15+15.8%298% | 13+4.7%125% | 12+6.3%— | 11+104%— | 5.6+143%— | 2.3—— | |
| Operating expenses | 37−40.2%— | 61−1.6%1243% | 62+31.3%615% | 47+12.4%— | 42+43.0%— | 29+124%— | 13—— | |
| Operating income | −37—— | −56—−1143% | −52—−515% | −47—— | −42—— | −29—— | −13—— | |
| Interest expense and finance costs | 0.1−70.7%— | 0.3−36.4%6.3% | 0.5+15.0%4.8% | 0.4+21.7%— | 0.3+6.8%— | 0.3+397%— | 0.1—— | |
| Other non-operating income (expense) | — | — | — | — | 0.1−40.5%— | 0.2+138%— | 0.1—— | |
| Income tax | 0—— | 0—0.0% | 0—0.0% | 0—— | 0—— | 0—— | 0—— | |
| Net income including minority interests | −39—— | −53—−1080% | −48—−475% | −46—— | −42—— | −30—— | −13—— | |
| Net income attributable to shareholders | −39—— | −53—−1080% | −48—−475% | −46—— | −42—— | −30—— | −13—— | |
| Earnings per share, basic | -50.83—— | -96.40r-1.29—— | -1.24—— | -1.96—— | -1.81—— | -4.93—— | -17.12—— | |
| Earnings per share, diluted | -50.83—— | -96.40r-1.29—— | -1.24—— | -1.96—— | -1.81—— | -4.93—— | -17.12—— | |
| Shares, weighted average (basic) | 0.8+39.3%— | 0.6r41−98.6%— | 39+63.7%— | 24+0.7%— | 23—— | — | — | |
| Shares, weighted average (diluted) | 0.8+39.3%— | 0.6r41−98.6%— | 39+63.7%— | 24+0.7%— | 23+290%— | 6.0+684%— | 0.8—— | |
| Balance sheet | ||||||||
| Cash and cash equivalents | 49+26.2%92.2% | 39−59.8%85.7% | 96+293%92.7% | 24−42.7%28.6% | 43−72.8%33.8% | 157+3905%96.5% | 3.9—83.6% | |
| Short-term investments | — | — | 0−100%0.0% | 55+18.1%63.7% | 46—36.5% | — | — | |
| Receivables | — | — | — | 0—0.0% | — | — | — | |
| Other current assets | 2.9+25.4%5.4% | 2.3+15.7%5.0% | 2.0+62.5%1.9% | 1.2+206%1.4% | 0.4r0.4+43.5%0.3% | 0.3−46.2%0.2% | 0.5—10.9% | |
| Current assets | 52+17.9%98.3% | 44−56.7%97.8% | 102+22.2%98.3% | 84−9.0%97.6% | 92−42.7%72.7% | 160+3348%98.5% | 4.7—99.1% | |
| Property, plant and equipment | — | — | — | — | 0.1+91.8%0.1% | 0.1—0.0% | — | |
| Right-of-use (leased) assets | — | — | — | 1.4−5.3%1.6% | 1.5−17.5%1.2% | 1.8—1.1% | — | |
| Long-term investments | — | — | — | 0−100%0.0% | 32—25.7% | — | — | |
| Total assets | 53+17.3%100% | 45−56.5%100% | 104+21.4%100% | 86−32.3%100% | 126−22.3%100% | 163+3372%100% | 4.7—100% | |
| Accounts payable | 0.9−27.2%1.8% | 1.3−61.1%2.9% | 3.3+134%3.2% | 1.4−49.5%1.7% | 2.8−22.2%2.2% | 3.6+93.2%2.2% | 1.9—40.0% | |
| Debt due within a year | 0−100%0.0% | 1.60.0%3.6% | 1.60.0%1.6% | 1.6—1.9% | 0−100%0.0% | 2.6+104%1.6% | 1.3—26.7% | |
| Current liabilities | 10−33.8%19.0% | 15−37.7%33.7% | 24+96.6%23.5% | 12+40.3%14.5% | 8.9−9.1%7.0% | 9.8+127%6.0% | 4.3—91.7% | |
| Long-term debt | 0−100%0.0% | 0.1−92.8%0.3% | 1.7−47.9%1.7% | 3.3−32.5%3.8% | 4.9+154%3.9% | 1.9−39.8%1.2% | 3.2—68.1% | |
| Lease liabilities (non-current) | 0.4−43.1%0.8% | 0.7−27.8%1.6% | 1.0−19.2%1.0% | 1.3−2.5%1.5% | 1.3−21.8%1.0% | 1.7—1.0% | — | |
| Total liabilities | 11−35.9%19.8% | 16−40.3%36.2% | 27+59.9%26.4% | 17+13.5%20.0% | 15+12.3%11.9% | 13+79.0%8.3% | 7.5—160% | |
| Retained earnings | −289—−546% | −250—−554% | −197—−190% | −149—−174% | −103—−81.5% | −61—−37.4% | −31—−667% | |
| Shareholders' equity | 43+47.5%80.2% | 29−62.3%63.8% | 77+11.7%73.6% | 68−38.5%80.0% | 111−25.5%88.1% | 149—91.7% | −31—−653% | |
| Total liabilities and equity | 53+17.3%100% | 45−56.5%100% | 104+21.4%100% | 86−32.3%100% | 126−22.3%100% | 163+3372%100% | 4.7—100% | |
| Shares outstanding | 1.4+144%— | 0.6r42−98.6%— | 41+73.8%— | 24+0.5%— | 23+1.0%— | 23+2943%— | 0.8—— | |
| Cash-flow statement | ||||||||
| Depreciation and amortization | 0.0−54.3%— | 0.0−34.3%0.9% | 0.1−5.4%0.7% | 0.1+8.8%— | 0.1+88.9%— | 0.0+200%— | 0.0—— | |
| Share-based compensation | 2.6−51.9%— | 5.3+15.7%109% | 4.6+27.3%45.8% | 3.6−8.3%— | 4.0+424%— | 0.8+285%— | 0.2—— | |
| Cash from operating activities | −33—— | −56—−1140% | −33—−330% | −42—— | −36—— | −28—— | −13—— | |
| Capital expenditure | — | 0—0.0% | −0.0—−0.1% | −0.0—— | −0.1—— | −0.1—— | −0.0—— | |
| Cash from investing activities | — | 0−100%0.0% | 56+135%553% | 24—— | −79—— | −0.1—— | −0.0—— | |
| Debt issued | — | — | — | 0−100%— | 5.0—— | — | 4.5—— | |
| Debt repaid | −2.1—— | −1.6—−33.0% | −1.6—−16.1% | 0—— | −4.8—— | — | — | |
| Cash from financing activities | 43—— | −1.6−103%−33.0% | 49—487% | −0.2−137%— | 0.6−99.6%— | 181+1356%— | 12—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | — | — | — | 0*−100%— | 0−100%— | 0−100%— | 0−100%— | 0.7*−75.9%100% | 0.6—100% | 1.6—100% | 2.0—100% | 2.9*—100% | |
| Research and development | 42+13.8%— | 18+262%— | 12—— | 7.6−30.1%— | 4.1*−80.9%— | 5.0−23.5%— | −0.4−105%— | 11+5.0%— | 21*+93.3%3078% | 6.6—1089% | 8.1—502% | 10—515% | 11*—384% | |
| General and administrative | 22+62.3%— | 5.8+81.7%— | 4.3+39.3%— | 4.4+20.7%— | 7.0*+111%— | 3.2−6.9%— | 3.1−12.2%— | 3.7−15.4%— | 3.3*+12.3%475% | 3.5—574% | 3.6—221% | 4.3—216% | 3.0*—102% | |
| Operating expenses | 64+26.7%— | 24+191%— | 17+513%— | 12−17.3%— | 11*−55.2%— | 8.2−17.8%— | 2.7−76.9%— | 14−1.0%— | 25*+76.3%3554% | 10—1663% | 12—723% | 15—731% | 14*—487% | |
| Operating income | −64—— | −24—— | −17—— | −12—— | −11*—— | −8.2—— | −2.7—— | −14—— | −24*—−3454% | −9.4—−1563% | −10—−623% | −13—−631% | −11*—−387% | |
| Interest expense and finance costs | 3.0+2027%— | 1.2+6221%— | 1.1+3683%— | 0.7+1772%— | 0.0*−89.3%— | 0.0−73.2%— | 0.0−65.1%— | 0.0−62.9%— | 0.1*−47.2%8.0% | 0.1—11.8% | 0.1—5.2% | 0.1—4.8% | 0.1*—3.7% | |
| Other non-operating income (expense) | — | — | — | — | — | — | — | — | — | 0.8—134% | 0.9—58.3% | 1.1—55.2% | — | |
| Net income including minority interests | −67—— | −24*—— | −16*—— | −12—— | −15*—— | −8.2*—— | −2.1*—— | −14—— | −24*—−3380% | −8.7*—−1440% | −9.2*—−570% | −12—−581% | −10.0*—−345% | |
| Net income attributable to shareholders | −67—— | −24—— | −16—— | −12—— | −15*—— | −8.2—— | −2.1—— | −14—— | −24*—−3380% | −8.7—−1440% | −9.2—−570% | −12—−581% | −10.0*—−345% | |
| Earnings per share, basic | — | -8.51—— | -6.68—— | -8.94—— | — | -14.58—— | -3.50—— | -23.95r-0.32—— | — | -15.75r-0.21—— | -16.73r-0.22—— | -0.28—— | — | |
| Earnings per share, diluted | — | -8.51—— | -6.68—— | -8.94—— | — | -14.58—— | -3.50—— | -23.95r-0.32—— | — | -15.75r-0.21—— | -16.73r-0.22—— | -0.28—— | — | |
| Shares, weighted average (basic) | 2.8+401%— | 2.8+401%— | 2.4+311%— | 1.4+134%— | — | 0.6+2.3%— | 0.6+7.7%— | 0.6r44−98.6%— | — | 0.6r41—— | 0.5r41—— | 41—— | — | |
| Shares, weighted average (diluted) | 2.8+401%— | 2.8+401%— | 2.4+311%— | 1.4+134%— | — | 0.6+2.3%— | 0.6+7.7%— | 0.6r44−98.6%— | — | 0.6r41—— | 0.5r41—— | 41—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 88—95.4% | 88+722%95.4% | 96+488%93.6% | 54+111%96.3% | 49+26.2%92.2% | 11−82.2%69.7% | 16−76.5%75.1% | 26−68.4%80.9% | 39−59.8%85.7% | 60—92.2% | 70—92.3% | 81—92.7% | 96—92.7% | |
| Short-term investments | — | — | — | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Other current assets | 0.2—0.2% | 0.2−93.0%0.2% | 0.2−91.3%0.2% | 0.1−95.7%0.2% | 2.9+25.4%5.4% | 2.9+239%19.0% | 2.7+76.2%12.4% | 2.1+28.0%6.5% | 2.3+15.7%5.0% | 0.9—1.3% | 1.5—2.0% | 1.6—1.8% | 2.0—1.9% | |
| Current assets | 90—98.2% | 90+522%98.2% | 101+383%98.3% | 55+80.0%98.0% | 52+17.9%98.3% | 15−77.2%94.8% | 21−71.7%96.0% | 31−64.4%96.6% | 44−56.7%97.8% | 64—97.7% | 74—97.9% | 86—98.1% | 102—98.3% | |
| Total assets | 92—100% | 92+500%100% | 103+371%100% | 56+77.5%100% | 53+17.3%100% | 15−76.5%100% | 22−71.1%100% | 32−63.8%100% | 45−56.5%100% | 65—100% | 76—100% | 88—100% | 104—100% | |
| Accounts payable | 2.7—3.0% | 2.7+97.1%3.0% | 1.2+49.8%1.2% | 2.7+42.8%4.8% | 0.9−27.2%1.8% | 1.4−23.0%9.1% | 0.8+18.3%3.7% | 1.9−0.6%5.9% | 1.3−61.1%2.9% | 1.8—2.8% | 0.7—0.9% | 1.9—2.2% | 3.3—3.2% | |
| Debt due within a year | 4.0—4.4% | 4.0+642%4.4% | 2.5+165%2.4% | 1.0−25.7%1.8% | 0−100%0.0% | 0.5−66.8%3.5% | 0.9−41.9%4.3% | 1.3−17.1%4.2% | 1.60.0%3.6% | 1.6—2.5% | 1.6—2.1% | 1.6—1.9% | 1.6—1.6% | |
| Current liabilities | 19—20.3% | 19+98.5%20.3% | 11+36.0%10.7% | 12−24.8%21.0% | 10−33.8%19.0% | 9.4−20.5%61.6% | 8.1−43.6%36.9% | 16−14.8%49.5% | 15−37.7%33.7% | 12—18.2% | 14—18.9% | 18—21.0% | 24—23.5% | |
| Long-term debt | 3.8—4.2% | 3.8—4.2% | 4.6—4.5% | 5.5—9.7% | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0.1−92.8%0.3% | 0.5—0.8% | 0.9—1.2% | 1.3—1.5% | 1.7—1.7% | |
| Lease liabilities (non-current) | 0.2—0.2% | 0.2−69.0%0.2% | 0.2−57.8%0.2% | 0.3−49.6%0.6% | 0.4−43.1%0.8% | 0.5—3.3% | 0.6—2.7% | 0.7−30.6%2.1% | 0.7−27.8%1.6% | — | — | 1.0—1.1% | 1.0—1.0% | |
| Total liabilities | 26—27.9% | 26+158%27.9% | 19+121%18.6% | 22+31.8%38.3% | 11−35.9%19.8% | 9.9−26.3%64.8% | 8.6−47.2%39.6% | 16−21.9%51.6% | 16−40.3%36.2% | 13—20.7% | 16—21.7% | 21—23.9% | 27—26.4% | |
| Retained earnings | −342—−372% | −342—−372% | −318—−309% | −302—−537% | −289—−546% | −275—−1793% | −266—−1221% | −264—−835% | −250—−554% | −227—−348% | −218—−289% | −209—−239% | −197—−190% | |
| Shareholders' equity | 66—72.1% | 66+1131%72.1% | 84+535%81.4% | 35+126%61.7% | 43+47.5%80.2% | 5.4−89.6%35.2% | 13−77.7%60.4% | 15−77.0%48.4% | 29−62.3%63.8% | 52—79.3% | 59—78.3% | 67—76.1% | 77—73.6% | |
| Total liabilities and equity | 92—100% | 92+500%100% | 103+371%100% | 56+77.5%100% | 53+17.3%100% | 15−76.5%100% | 22−71.1%100% | 32−63.8%100% | 45−56.5%100% | 65—100% | 76—100% | 88—100% | 104—100% | |
| Shares outstanding | 2.9—— | 2.9+410%— | 2.8+389%— | 1.4−96.8%— | 1.4+144%— | 0.6−98.6%— | 0.6−98.6%— | 42+2.6%— | 0.6r42−98.6%— | 41—— | 41—— | 41—— | 41—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 1.6+6404%— | 0.7*+24500%— | 0.6*+8914%— | 0.3+4100%— | 0.0*−44.4%— | 0.0*−70.0%— | 0.0*−41.7%— | 0.0−60.0%— | 0.0*−43.8%1.3% | 0.0*—1.7% | 0.0*—0.7% | 0.0—0.7% | 0.0*—0.6% | |
| Share-based compensation | 4.4+136%— | 1.1+166%— | 0.9—— | 0.7+26.7%— | 1.7*+76.1%— | 0.4−63.6%— | −0.1−105%— | 0.5−65.2%— | 1.0*−21.3%138% | 1.1—189% | 1.7—105% | 1.6—78.0% | 1.2*—42.3% | |
| Cash from operating activities | −51—— | −14*—— | −22*—— | −8.7—— | −6.5*—— | −5.3*—— | −8.8*—— | −13—— | −21*—−2967% | −9.2*—−1532% | −11*—−690% | −15—−747% | −11*—−388% | |
| Capital expenditure | — | 0*—— | −0.1*—— | −0.0—— | — | 0*—— | 0*—— | 0—— | 0*—0.0% | — | — | — | 0*—0.0% | |
| Cash from investing activities | — | 0*—— | −0.1*—— | −0.0—— | — | 0*—— | 0*—— | 0—— | 0*−100%0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | 9.3*—322% | |
| Debt issued | — | 0.1*—— | 0*—— | 14—— | — | 0*—— | 0*—— | 0—— | — | — | — | — | — | |
| Debt repaid | −0.8—— | 0*—— | 0*—— | 0—— | −0.8*—— | −0.4*—— | −0.4*—— | −0.4—— | −0.4*—−58.2% | −0.4*—−67.3% | −0.4*—−25.2% | −0.4—−20.2% | −0.4*—−14.1% | |
| Cash from financing activities | 128—— | 5.2*—— | 64*—— | 14—— | 45*—— | −0.4*—— | −0.4*—— | −0.4—— | −0.6*—−89.7% | −0.4*—−67.3% | −0.4*—−22.7% | −0.2—−11.3% | −0.6*—−19.1% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Spruce Biosciences, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Javier Szwarcberg | $2.9 M | $4.2 M | $1.3 M | $40 |
| 2024Javier Szwarcberg | $1.5 M | −$993 K | $1.0 M | $14 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Spruce Biosciences, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 3 · Restructuring 1 · Directors and officers 6 · Material agreement 5 · Agreement ended 2 · New debt 1 · Unregistered share sale 3 · Shareholder rights changed 2 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 12
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Agreement ended | 8-K | |
| Directors and officersMaterial agreementAgreement endedResults announced | 8-K | |
| Material agreementNew debtUnregistered share saleResults announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Shareholder rights changedBylaws or fiscal year changedShareholder vote | 8-K | |
| Delisting notice | 8-K | |
| Material agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Delisting noticeRestructuring | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2025 | $50 M | Private placement after listing | $50 to $250 million | 21 | equity, options | SEC |
| Feb 2023 | $54 M | Private placement after listing | $50 to $250 million | 20 | equity, options | SEC |
| Feb 2020 | $88 M | No. 1 | $50 to $250 million | 11 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Spruce Biosciences, Inc.#
1 labor condition applications certified in fiscal 2025 for 1 positions, at a median wage of $266 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Senior Director of CMC OperationsNatural Sciences Managers | 1 | $266 K |
Where: South San Francisco, CA 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2025 | 1 | 1 | $266 K | 1 |
| FY2022 | 1 | 1 | $218 K | 1 |
| FY2020 | 1 | 1 | $210 K | 1 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Spruce Biosciences, Inc.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2024 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Spruce Biosciences, Inc. compares in Biotechnology
- Market cap$130 M · higher than 40% of 726
- Revenue growth-51.3% · higher than 17% of 438
- Price / book3.0× · lower than 48% of 534
- FCF yield-43.1% · higher than 27% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Spruce Biosciences, Inc.🇺🇸 | $130 M | — | — | -51.3% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 26, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Spruce Biosciences, Inc.? Verify and update this profile — free
Show Spruce Biosciences, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.